Chen Wei team's vaccine release phase three data experts: suitable for rapid mass vaccination

Pharma.com, Feb. 9 (Xinhua) -- Following the release of phase III clinical data on two inactivated vaccines from China Bio and Koxing Zhongwei, another technical route for the deployment of China's new crown vaccine, the latest data on Ad5-nCoV, an adenovirus vector vaccine developed by the team of Chen Wei academicians of the Academy of Military Sciences and Concino Bio, was released on the 8th.
Health officials in Pakistan announced the same day, Ad5-nCoV in Pakistan, the third phase of clinical trials in the medium-term analysis results show that after a single shot of vaccination, the vaccine on the protection of severe neo-crown pneumonia 100%, the overall protection effect of 74.8%.
the Ad5-nCoV vaccine developed by Chen Wei's team is the world's first new crown vaccine to enter the clinical research phase, and is currently one of the only single-shot vaccines in the world that has released phase III trial data, several experts told global Times reporters, the effectiveness of the vaccine data is very good, and single-shot vaccination means that large-scale rapid vaccination of the population, the overall social epidemic prevention strategy is of great importance.
Pakistan's Special Assistant to the Prime Minister for National Health, Fesso Sultan, said on the 8th local time, Ad5-nCoV (also known as "Kwisha" or "Convidecia") in Pakistan, the third phase of clinical trials in the analysis showed that after 28 days of single-shot vaccination, the vaccine on the protection of severe neo-crown pneumonia 100%, the overall protection effect of 74.8%, no serious adverse reactions related to the vaccine.
officials also revealed that Ad5-nCoV's phase III clinical trial data show that after 28 days of single-shot vaccination, the vaccine has a protective effect of 90.98 percent on severe neo-crown pneumonia and an overall protective effect of 65.7 percent.
phase III clinical trial of Ad5-nCoV has been completed in 78 clinical centers in five countries to vaccinate more than 40,000 subjects, according to a statement released by Consino Bio1.
that countries where Ad5-nCoV conducts Phase III clinical trials include Mexico, Russia, Pakistan, Argentina and Chile.
Ad5-nCoV was developed by the team of Chen Wei, a member of the Institute of Bioengineering of the Institute of Military Medicine of the Academy of Military Sciences, in collaboration with Concino Bio, and launched Phase I and Phase II clinical trials in Wuhan on March 16 and April 12 last year, respectively, and is the world's first new crown vaccine to enter the clinical research phase.
clinical trial results initially proved the vaccine to be safe, and data from both phases of clinical trials were published in The Lancet, an internationally renowned medical journal.
A Chinese expert in immunology told the Global Times on the 8th, Ad5-nCoV's effectiveness data is very good, especially considering that it is one of the few single-shot new crown vaccine, in the absence of a second needle to enhance the effect, the moderate antibody titration is difficult to reach a very high level.
if you have to compare horizontally, the effectiveness of Ad5-nCoV should be compared to the data after the first shot of other vaccines," he said.
" vaccine professional Zhuang Shili and doctors also told the Global Times reporter the same day, although on the face of it, the overall efficiency of the vaccine seems to be lower than several other adenovirus vector vaccine, but to consider an important prerequisite, namely, the Consino vaccine is one of the rare single-shot vaccination.
Currently, the same technology route as consino vaccines is developed globally, including the Oxford/AstraZeneta vaccine (AZD1222), the Johnson and Johnson vaccine (Ad26.COV2.S) and the Russian "satellite V", of which only the Consino vaccine and the Johnson vaccine are single-shot vaccines.
On January 29 this year, Johnson and Johnson announced the results of phase III clinical trials of its vaccine, showing that after 28 days of single doses of the new crown vaccine, the total effectiveness rate of moderate and severe neocytic coronary pneumonia was 66%, and the effective rate of prevention of serious diseases in all study areas was 85%.
, the Johnson and Johnson vaccine, while also a single shot, gives an effective rate of 66% that is non-mild, and that 85% of its severity prevention is less effective than Ad5-nCoV's 90.98 percent.
" specifically, in the adenovirus vector vaccine, the Oxford/ AstraZeneta vaccine data is more confusing, overall the efficiency of the two needles is not high, only 70%; 6%, is the only overall effectiveness of more than 90% of the adenovirus vector vaccine, and according to its paper published in The Lancet, the 'satellite V' after the first shot of the effective rate of 73.1%, is also a good data.
overall, the Connestino vaccine is 65.7 percent effective, which is a very good result.
" Zhuang Shili and said.
the immunology expert analysis, the single-shot vaccination process is simple, can be inoculated in the same period of time more people, that is, to help protect as many people as possible in the shortest possible time.
also believes that Ad5-nCoV can achieve rapid mass vaccination of the population, and that the 90% rate of severe prevention means that the pressure on hospital beds can be greatly reduced.
is understood that another advantage of the Consino vaccine is that it only needs to be stored at 2 to 8 degrees Celsius and is suitable for transport and distribution.
, however, the data released by Pakistan did not say whether the effectiveness of the Consino vaccine would be affected by the virus mutation.
, Johnson and Johnson, AstraZeneta and others have reported a decrease in the vaccine's protection against the South African strain.
In addition, immunologists interviewed by the Global Times added that further data on adverse reactions to the Consino vaccine need to be looked at, as the adenovirus vector vaccine is essentially a cold virus that can cause some cold symptoms during the vaccination process, and whether it is recommended for the less healthy population to receive such a vaccine requires further observation.